2023
Converging Evidence from Rodent and Human Studies on the Role of Spironolactone as a Potential Pharmacotherapy for Alcohol Use Disorder
Farokhnia M, Rentsch C, Chuong V, McGinn M, Elvig S, Douglass E, Gonzalez L, Sanfilippo J, Marchette R, Tunstall B, Fiellin D, Koob G, Justice A, Leggio L, Vendruscolo L. Converging Evidence from Rodent and Human Studies on the Role of Spironolactone as a Potential Pharmacotherapy for Alcohol Use Disorder. Alcohol 2023, 109: 83-84. DOI: 10.1016/j.alcohol.2023.03.071.Peer-Reviewed Original ResearchRacial and Ethnic Bias in the Diagnosis of Alcohol Use Disorder in Veterans
Vickers-Smith R, Justice A, Becker W, Rentsch C, Curtis B, Fernander A, Hartwell E, Ighodaro E, Kember R, Tate J, Kranzler H. Racial and Ethnic Bias in the Diagnosis of Alcohol Use Disorder in Veterans. American Journal Of Psychiatry 2023, 180: 426-436. PMID: 37132202, PMCID: PMC10238581, DOI: 10.1176/appi.ajp.21111097.Peer-Reviewed Original ResearchConceptsAlcohol use disorderAlcohol consumptionAUD diagnosisHispanic veteransWhite veteransUse disordersPrevalence of AUDAlcohol Use Disorders Identification TestUnhealthy alcohol useICD-10 codesAUDIT-C scoresSelf-reported alcohol consumptionAlcohol-related disordersDiagnosis of AUDDisorders Identification TestMaximum scoreSelf-reported raceElectronic health recordsPrimary outcomeAlcohol consumption levelsPotential confoundersHigh prevalenceMillion Veteran ProgramGreater oddsICD-9
2022
Association Between Alcohol Use Disorder and Receipt of Direct-Acting Antiviral Hepatitis C Virus Treatment
Haque L, Fiellin D, Tate J, Esserman D, Bhattacharya D, Butt A, Crystal S, Edelman E, Gordon A, Lim J, Tetrault J, Williams E, Bryant K, Cartwright E, Rentsch C, Justice A, Re V, McGinnis K. Association Between Alcohol Use Disorder and Receipt of Direct-Acting Antiviral Hepatitis C Virus Treatment. JAMA Network Open 2022, 5: e2246604. PMID: 36515952, PMCID: PMC9856353, DOI: 10.1001/jamanetworkopen.2022.46604.Peer-Reviewed Original ResearchConceptsCurrent alcohol use disorderLow-risk drinkingAlcohol use disorderVeterans Health AdministrationHistory of AUDDAA treatmentAlcohol use categoriesAUD historyCohort studyRisk drinkingUse disordersDirect acting antiviral (DAA) treatmentAlcohol Use Disorders Identification Test-Consumption (AUDIT-C) questionnaireHepatitis C virus infectionHepatitis C virus (HCV) treatmentCox proportional hazards regressionC virus infectionC virus treatmentProportional hazards regressionTenth Revision diagnosisAUDIT-C questionnaireInternational Statistical ClassificationRelated Health ProblemsAntiviral treatmentRevision diagnosisCross-ancestry meta-analysis of opioid use disorder uncovers novel loci with predominant effects in brain regions associated with addiction
Kember RL, Vickers-Smith R, Xu H, Toikumo S, Niarchou M, Zhou H, Hartwell EE, Crist RC, Rentsch CT, Davis L, Justice A, Sanchez-Roige S, Kampman K, Gelernter J, Kranzler H. Cross-ancestry meta-analysis of opioid use disorder uncovers novel loci with predominant effects in brain regions associated with addiction. Nature Neuroscience 2022, 25: 1279-1287. PMID: 36171425, PMCID: PMC9682545, DOI: 10.1038/s41593-022-01160-z.Peer-Reviewed Original ResearchConceptsOpioid use disorderGenome-wide association studiesWide significant lociGene expression enrichmentSignificant genetic correlationsCell type groupSignificant lociAssociation studiesExpression enrichmentMillion Veteran ProgramGenetic correlationsUse disordersLociBrain regionsExonic variantsIntronic variantsSubstance use disordersTraitsBiological basisOpioid epidemicPsychiatric disordersVeteran ProgramBrain diseasesTSNARE1FBXW4Spironolactone as a potential new pharmacotherapy for alcohol use disorder: convergent evidence from rodent and human studies
Farokhnia M, Rentsch CT, Chuong V, McGinn MA, Elvig SK, Douglass EA, Gonzalez LA, Sanfilippo JE, Marchette RCN, Tunstall BJ, Fiellin DA, Koob GF, Justice AC, Leggio L, Vendruscolo LF. Spironolactone as a potential new pharmacotherapy for alcohol use disorder: convergent evidence from rodent and human studies. Molecular Psychiatry 2022, 27: 4642-4652. PMID: 36123420, PMCID: PMC10231646, DOI: 10.1038/s41380-022-01736-y.Peer-Reviewed Original ResearchConceptsAlcohol use disorderAlcohol Use Disorders Identification Test-ConsumptionEffect of spironolactoneAlcohol consumptionSpironolactone doseNovel pharmacotherapiesUse disordersHuman studiesLarge integrated healthcare systemHeavy episodic alcohol consumptionAlcohol-induced ataxiaMineralocorticoid receptor antagonistsSelf-reported alcohol consumptionBlood alcohol levelsEpisodic alcohol consumptionIntegrated healthcare systemPharmacoepidemiologic cohort studyPotential new pharmacotherapiesCohort studyAlcohol drinkingReceptor antagonistFemale miceFemale ratsNew pharmacotherapiesRat modelAssociation of topiramate prescribed for any indication with reduced alcohol consumption in electronic health record data
Kranzler HR, Leong SH, Naps M, Hartwell EE, Fiellin DA, Rentsch CT. Association of topiramate prescribed for any indication with reduced alcohol consumption in electronic health record data. Addiction 2022, 117: 2826-2836. PMID: 35768956, PMCID: PMC10317468, DOI: 10.1111/add.15980.Peer-Reviewed Original ResearchConceptsAUDIT-C scoresAlcohol use disorderElectronic health record dataHealth record dataUse disordersNEG patientsTopiramate dosageAlcohol Use Disorders Identification Test-Consumption scoresPropensity score-matched groupsHistory of AUDParallel group comparisonPropensity score-matched comparison groupRecord dataBaseline drinking levelsReduced alcohol consumptionHealth care systemTopiramate prescriptionsPre-post differencesAUD historyTopiramate's effectsPatientsRecord diagnosisAlcohol consumptionTopiramateComparison group
2020
Association of OPRM1 Functional Coding Variant With Opioid Use Disorder
Zhou H, Rentsch CT, Cheng Z, Kember RL, Nunez YZ, Sherva RM, Tate JP, Dao C, Xu K, Polimanti R, Farrer LA, Justice AC, Kranzler HR, Gelernter J. Association of OPRM1 Functional Coding Variant With Opioid Use Disorder. JAMA Psychiatry 2020, 77: 1072-1080. PMID: 32492095, PMCID: PMC7270886, DOI: 10.1001/jamapsychiatry.2020.1206.Peer-Reviewed Original ResearchConceptsOpioid use disorderUse disordersMendelian randomization analysisAfrican American individualsMAIN OUTCOMEFunctional coding variantSignificant associationCausal associationRandomization analysisElectronic health record dataCurrent opioid crisisAmerican individualsHealth record dataCognitive performanceInternational Statistical ClassificationRelated Health ProblemsPotential causal associationAmerican controlsEuropean American controlsAfrican-American controlsCoding variantBuprenorphine treatmentOUD diagnosisTobacco smokingNinth RevisionSafety of Gabapentin Prescribed for Any Indication in a Large Clinical Cohort of 571,718 US Veterans with and without Alcohol Use Disorder
Rentsch CT, Morford KL, Fiellin DA, Bryant KJ, Justice AC, Tate JP. Safety of Gabapentin Prescribed for Any Indication in a Large Clinical Cohort of 571,718 US Veterans with and without Alcohol Use Disorder. Alcohol Clinical And Experimental Research 2020, 44: 1807-1815. PMID: 32628784, PMCID: PMC7540277, DOI: 10.1111/acer.14408.Peer-Reviewed Original ResearchConceptsAlcohol use disorderMental statusRelative riskGabapentin exposureUse disordersICD-9 diagnostic codesAdverse neurologic effectsPotential medication interactionsAltered mental statusIncidence of fallsClear dose-response relationshipLarge clinical cohortDose-response relationshipRace/ethnicityUnexposed patientsHepatitis CAdverse eventsMedication interactionsExcess riskNeurologic effectsUS veteransDiagnostic codesIncidence rateClinical cohortHigh risk
2019
FUNCTIONAL CODING VARIANT IN OPRM1 GENE ASSOCIATED WITH OPIOID USE DISORDER: EVIDENCE FROM GWAS ON LARGE COHORTS
Zhou H, Rentsch C, Cheng Z, Kember R, Nunex Y, Tate J, Dao C, Polimanti R, Justice A, Kranzler H, Gelernter J. FUNCTIONAL CODING VARIANT IN OPRM1 GENE ASSOCIATED WITH OPIOID USE DISORDER: EVIDENCE FROM GWAS ON LARGE COHORTS. European Neuropsychopharmacology 2019, 29: s34-s35. DOI: 10.1016/j.euroneuro.2019.07.070.Peer-Reviewed Original ResearchPatterns and Correlates of Prescription Opioid Receipt Among US Veterans: A National, 18-Year Observational Cohort Study
Rentsch CT, Edelman EJ, Justice AC, Marshall BDL, Xu K, Smith AH, Crystal S, Gaither JR, Gordon AJ, Smith RV, Kember RL, Polimanti R, Gelernter J, Fiellin DA, Tate JP, Kranzler HR, Becker WC. Patterns and Correlates of Prescription Opioid Receipt Among US Veterans: A National, 18-Year Observational Cohort Study. AIDS And Behavior 2019, 23: 3340-3349. PMID: 31317364, PMCID: PMC7344341, DOI: 10.1007/s10461-019-02608-3.Peer-Reviewed Original ResearchConceptsOpioid use disorderOpioid receiptCohort studyLong-term opioid therapyVeterans Aging Cohort StudyLatent growth mixture modellingPrescription opioid receiptObservational cohort studyAging Cohort StudyOpioid therapyCause mortalityHepatitis COpioid prescriptionsFuture prevention researchOUD diagnosisGrowth mixture modellingUS veteransHigh prevalenceLow doseHigh incidenceUse disordersPrevention researchGenetic discoveriesReceiptHIVAssociation Between Gabapentin Receipt for Any Indication and Alcohol Use Disorders Identification Test—Consumption Scores Among Clinical Subpopulations With and Without Alcohol Use Disorder
Rentsch CT, Fiellin DA, Bryant KJ, Justice AC, Tate JP. Association Between Gabapentin Receipt for Any Indication and Alcohol Use Disorders Identification Test—Consumption Scores Among Clinical Subpopulations With and Without Alcohol Use Disorder. Alcohol Clinical And Experimental Research 2019, 43: 522-530. PMID: 30620410, PMCID: PMC6397056, DOI: 10.1111/acer.13953.Peer-Reviewed Original ResearchConceptsAlcohol use disorderAlcohol Use Disorders Identification Test-Consumption scoresAUDIT-C scoresAlcohol consumptionUnexposed patientsClinical trialsUse disordersBaseline levelsVeterans Aging Cohort StudyDoses of gabapentinAging Cohort StudyImpact of gabapentinSubstance use treatmentDifferences linear regression modelGabapentin doseCohort studyCurrent medicationsBaseline auditMultivariable differenceClinical indicationsAUD historyPatientsGabapentinClinical subpopulationsConsecutive days